Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus
Authors' conclusion
AH use can reduce HCC risk in T2DM patients without HBV or HCV infection in a dose-dependent manner.
Study context
- Population
- Patients with T2D without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, Taiwan's National Health Insurance Research Database, 2008–2018matched cohort
- Participants
- 47,990 vs 47,990
- Exposure
- H1-antihistamine use vs nonuse
- AH usersn = 47,990
- Nonusersn = 47,990reference
- Outcome
- Hepatocellular carcinoma (HCC) risk
Methodological details1:1 propensity score matched, population-based database
- 1:1 propensity score matched
- Population-based database
Main finding
As reported in the abstract
HCC risk
Each group vs nonusersEstimate (95% CI)
AH users
aHR 0.55(0.46–0.67)
AH users
IRR 0.70(0.60–0.84)
Observational data: associations, not effects.
Further findings
Dose-response: Hepatocellular carcinoma (HCC) risk by cumulative defined daily doses of AH
- aHR, 28-35 cumulative DDD
- 0.58
- aHR, 36-49 cumulative DDD
- 0.56
- aHR, 50-77 cumulative DDD
- 0.50
- aHR, >77 cumulative DDD
- 0.41
Original publication
Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus. Diabetes Metab. Published 25 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →